Skip to main content
. 2022 Nov 3;8(2):e002477. doi: 10.1136/rmdopen-2022-002477

Figure 2.

Figure 2

Modified Rodnan skin score (mRSS) and FVC at follow-up (12±3) months. (A) Primary outcome mRSS estimate (95% CI) tocilizumab (TCZ) vs control between-group mean difference p=0.48. (B) Primary outcome FVC% predicted estimate (95% CI) TCZ vs control between-group difference p=0.70.